Christian Klein
Christian Klein
Roche Pharma Research and Early Development, Roche Innovation Center Zurich
Dirección de correo verificada de roche.com
Título
Citado por
Citado por
Año
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev, BT Vu, B Graves, D Carvajal, F Podlaski, Z Filipovic, N Kong, ...
Science 303 (5659), 844-848, 2004
46452004
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell …
E Mössner, P Brünker, S Moser, U Püntener, C Schmidt, S Herter, R Grau, ...
Blood 115 (22), 4393-4402, 2010
7952010
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ...
The Journal of clinical investigation 122 (6), 1991-2005, 2012
3832012
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ...
Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011
3452011
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53
R Stoll, C Renner, S Hansen, S Palme, C Klein, A Belling, W Zeslawski, ...
Biochemistry 40 (2), 336-344, 2001
3392001
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ...
Nature medicine 24 (7), 994-1004, 2018
3372018
p53 contains large unstructured regions in its native state
S Bell, C Klein, L Müller, S Hansen, J Buchner
Journal of molecular biology 322 (5), 917-927, 2002
3162002
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models
S Herter, F Herting, O Mundigl, I Waldhauer, T Weinzierl, T Fauti, G Muth, ...
Molecular cancer therapeutics 12 (10), 2031-2042, 2013
2712013
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization
Y Tomita, N Marchenko, S Erster, A Nemajerova, A Dehner, C Klein, ...
Journal of Biological Chemistry 281 (13), 8600-8606, 2006
2632006
The N-terminal domain of p53 is natively unfolded
R Dawson, L Müller, A Dehner, C Klein, H Kessler, J Buchner
Journal of molecular biology 332 (5), 1131-1141, 2003
2592003
Targeting the p53–MDM2 interaction to treat cancer
C Klein, LT Vassilev
British journal of cancer 91 (8), 1415-1419, 2004
2282004
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
G Niederfellner, A Lammens, O Mundigl, GJ Georges, W Schaefer, ...
Blood, The Journal of the American Society of Hematology 118 (2), 358-367, 2011
2222011
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
J Golay, F Da Roit, L Bologna, C Ferrara, JH Leusen, A Rambaldi, C Klein, ...
Blood 122 (20), 3482-3491, 2013
2132013
Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors
DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ...
Cancer immunology research 3 (12), 1344-1355, 2015
2062015
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
C Klein, A Lammens, W Schäfer, G Georges, M Schwaiger, E Mössner, ...
MAbs 5 (1), 22-33, 2013
2012013
A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors
M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ...
Clinical Cancer Research 22 (13), 3286-3297, 2016
1812016
Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment
A Seckinger, JA Delgado, S Moser, L Moreno, B Neuber, A Grab, S Lipp, ...
Cancer cell 31 (3), 396-410, 2017
1662017
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic …
Y Kienast, C Klein, W Scheuer, R Raemsch, E Lorenzon, D Bernicke, ...
Clinical Cancer Research 19 (24), 6730-6740, 2013
1602013
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
C Klein, C Sustmann, M Thomas, K Stubenrauch, R Croasdale, ...
MAbs 4 (6), 653-663, 2012
1552012
Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
M Patz, P Isaeva, N Forcob, B Müller, LP Frenzel, CM Wendtner, C Klein, ...
British journal of haematology 152 (3), 295-306, 2011
1382011
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20